NPM1 and acute myeloid leukemia: The consensus from the European Leukemia Network (ELN) MRD Working Party recommends that AML patients with NPM1 mutations undergo molecular MRD evaluation at the following clinical timepoints: at diagnosis, after 2 cycles of induction/consolidation chemotherapy, and at the end of treatment [78].